ImmuPharma PLC (AIM: IMM) said it is actively progressing partnering discussions for its lead autoimmune platform, P140, which remains its primary strategic focus for 2026.
The update followed shareholder approval of two fundraising resolutions. A £6 million Lanstead subscription passed with 91.46% support, while a £468,000 WRAP retail offer secured 88.91% backing. The combined £6.5 million raise extends the company’s cash runway into at least the second half of 2028.
Chairman Tim McCarthy said the strengthened balance sheet positions the company to negotiate a potential P140 licensing deal from a position of financial strength. P140 is a peptide-based therapy targeting autoimmune diseases, including lupus.
The programme has also been supported by progress on intellectual property, with a Combined Search and Examination Report issued for its UK patent application, alongside new study data. A scientific manuscript is currently being prepared for submission to a peer-reviewed journal.
In parallel, ImmuPharma is advancing its second asset, Kapiglucagon, a treatment candidate for type 1 diabetes. The company has launched an accelerated two-year development programme, with further updates expected as it moves toward potential partnering opportunities.
The Lanstead funding structure is based on an 8p benchmark price, offering potential upside participation linked to future share price performance.
